Loading the company…
Loading the company…
In the last ten years FDA made 0 decisions for Lemaitre Vascular (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 1 procedure family. The latest was on 2013-02-05.
| Family | Decisions on record |
|---|---|
| Dialysis access | 1 |
| Date | Kind | Number | Device |
|---|---|---|---|
| 2013-02-05 | 510(k) | K130016 | LIFESPAN EPTFE VASCULAR GRAFT |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Lemaitre Vascular.
In 2025, Lemaitre Vascular reported engagement with 1,987 surgeons and other clinicians in the states MedaRep covers, worth $366K in consulting, speaking, meals and travel for its device products, the most in Illinois ($141K to 88). Royalties are left out.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: Illinois ($141K, 88 engaged), New York ($47K, 91 engaged), New Jersey ($39K, 82 engaged), Ohio ($32K, 79 engaged), California ($19K, 157 engaged).